Insider purchase at Amicus Therapeutics (FOLD) prolongs buy activity of Last 90 Days

Wednesday, March 07, 2018 10:15 PM ET

Insider purchase at Amicus Therapeutics (FOLD) prolongs buy activity of Last 90 Days

One insider — Perceptive Advisors Llc, 10% Owner — today, acquired 335,827 shares of Amicus Therapeutics having a market value of approximately $4,553,814, as disclosed in a form 4 document filed with the SEC. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the purchase of 300,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 635,827 shares and have averaged 317,914 shares per transaction over this time period.

Insider buy/sell trading at Amicus Therapeutics is higher than the 121 peer company average over the last 90-day period. The Pharmaceuticals peer group saw 84 buy/sell trades during this period for an average of 0.7 transactions per company. The number of shares per buy/sell trade for Amicus Therapeutics insiders was also higher. Within the peer group there were 2,793,849 shares purchased and 4,205,165 shares sold with company insiders having sold 16,801 shares on average.

Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data used in creating and writing this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.